Φορτώνει......
厄洛替尼治疗晚期非小细胞肺癌分类及回归树分析
BACKGROUND AND OBJECTIVE: Erlotinib is a targeted therapy drug for non-small cell lung cancer (NSCLC). It has been proven that, there was evidence of various survival benefits derived from erlotinib in patients with different clinical features, but the results are conflicting. The aim of this study...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
中国肺癌杂志编辑部
2011
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5999942/ https://ncbi.nlm.nih.gov/pubmed/22008108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2011.10.04 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|